363 related articles for article (PubMed ID: 29388517)
21. Neurobiology of the Rapid-Acting Antidepressant Effects of Ketamine: Impact and Opportunities.
Shinohara R; Aghajanian GK; Abdallah CG
Biol Psychiatry; 2021 Jul; 90(2):85-95. PubMed ID: 33568318
[TBL] [Abstract][Full Text] [Related]
22. The role of mTOR in depression and antidepressant responses.
Abelaira HM; Réus GZ; Neotti MV; Quevedo J
Life Sci; 2014 Apr; 101(1-2):10-4. PubMed ID: 24582593
[TBL] [Abstract][Full Text] [Related]
23. [The next psychoactive drugs: From imipramine to ketamine].
Carrillo P; Petit AC; Gaillard R; Vinckier F
Bull Acad Natl Med; 2020 Dec; 204(9):1034-1042. PubMed ID: 32963409
[TBL] [Abstract][Full Text] [Related]
24. Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.
Ionescu DF; Felicione JM; Gosai A; Cusin C; Shin P; Shapero BG; Deckersbach T
Harv Rev Psychiatry; 2018; 26(6):320-339. PubMed ID: 29465479
[TBL] [Abstract][Full Text] [Related]
25. Relationship of ketamine's antidepressant and psychotomimetic effects in unipolar depression.
Sos P; Klirova M; Novak T; Kohutova B; Horacek J; Palenicek T
Neuro Endocrinol Lett; 2013; 34(4):287-93. PubMed ID: 23803871
[TBL] [Abstract][Full Text] [Related]
26. A brief history of the development of antidepressant drugs: from monoamines to glutamate.
Hillhouse TM; Porter JH
Exp Clin Psychopharmacol; 2015 Feb; 23(1):1-21. PubMed ID: 25643025
[TBL] [Abstract][Full Text] [Related]
27. Synaptic mechanisms underlying rapid antidepressant action of ketamine.
Kavalali ET; Monteggia LM
Am J Psychiatry; 2012 Nov; 169(11):1150-6. PubMed ID: 23534055
[TBL] [Abstract][Full Text] [Related]
28. Chronic stress pathology and ketamine-induced alterations in functional connectivity in major depressive disorder: An abridged review of the clinical evidence.
Averill LA; Fouda S; Murrough JW; Abdallah CG
Adv Pharmacol; 2020; 89():163-194. PubMed ID: 32616206
[TBL] [Abstract][Full Text] [Related]
29. The role of glutamatergic modulation in the mechanism of action of ketamine, a prototype rapid-acting antidepressant drug.
Pałucha-Poniewiera A
Pharmacol Rep; 2018 Oct; 70(5):837-846. PubMed ID: 30086517
[TBL] [Abstract][Full Text] [Related]
30. Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants.
Gould TD; Zarate CA; Thompson SM
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():213-236. PubMed ID: 30296896
[TBL] [Abstract][Full Text] [Related]
31. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Maeng S; Zarate CA; Du J; Schloesser RJ; McCammon J; Chen G; Manji HK
Biol Psychiatry; 2008 Feb; 63(4):349-52. PubMed ID: 17643398
[TBL] [Abstract][Full Text] [Related]
32. Impact of subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo electrophysiological study on monoaminergic and glutamatergic neurons.
El Iskandrani KS; Oosterhof CA; El Mansari M; Blier P
J Psychopharmacol; 2015 Jul; 29(7):792-801. PubMed ID: 25759403
[TBL] [Abstract][Full Text] [Related]
33. Ketamine's antidepressant action: beyond NMDA receptor inhibition.
Hashimoto K
Expert Opin Ther Targets; 2016 Nov; 20(11):1389-1392. PubMed ID: 27646666
[TBL] [Abstract][Full Text] [Related]
34. Ketamine and other potential glutamate antidepressants.
Dutta A; McKie S; Deakin JFW
Psychiatry Res; 2015 Jan; 225(1-2):1-13. PubMed ID: 25467702
[TBL] [Abstract][Full Text] [Related]
35. Lateral Habenular Burst Firing as a Target of the Rapid Antidepressant Effects of Ketamine.
Cui Y; Hu S; Hu H
Trends Neurosci; 2019 Mar; 42(3):179-191. PubMed ID: 30823984
[TBL] [Abstract][Full Text] [Related]
36. The antidepressant-like effects of glutamatergic drugs ketamine and AMPA receptor potentiator LY 451646 are preserved in bdnf⁺/⁻ heterozygous null mice.
Lindholm JS; Autio H; Vesa L; Antila H; Lindemann L; Hoener MC; Skolnick P; Rantamäki T; Castrén E
Neuropharmacology; 2012 Jan; 62(1):391-7. PubMed ID: 21867718
[TBL] [Abstract][Full Text] [Related]
37. Crosstalk Between Inflammation and Glutamate System in Depression: Signaling Pathway and Molecular Biomarkers for Ketamine's Antidepressant Effect.
Cui W; Ning Y; Hong W; Wang J; Liu Z; Li MD
Mol Neurobiol; 2019 May; 56(5):3484-3500. PubMed ID: 30140973
[TBL] [Abstract][Full Text] [Related]
38. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder.
Niciu MJ; Ionescu DF; Richards EM; Zarate CA
J Neural Transm (Vienna); 2014 Aug; 121(8):907-24. PubMed ID: 24318540
[TBL] [Abstract][Full Text] [Related]
39. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism.
Pilc A; Machaczka A; Kawalec P; Smith JL; Witkin JM
Expert Opin Drug Discov; 2022 Oct; 17(10):1131-1146. PubMed ID: 35934973
[TBL] [Abstract][Full Text] [Related]
40. Monoaminergic system and depression.
Perez-Caballero L; Torres-Sanchez S; Romero-López-Alberca C; González-Saiz F; Mico JA; Berrocoso E
Cell Tissue Res; 2019 Jul; 377(1):107-113. PubMed ID: 30627806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
